Gene Therapy Focus SwanBio Therapeutics, now part of Spur Therapeutics, is developing a potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN). This innovative approach in biotechnology research presents a unique sales opportunity for partnerships and collaborations within the gene therapy and rare disease treatment space.
Expanding Pipeline Being part of an expanding pipeline of genetic medicines at Spur Therapeutics indicates growth potential and opens doors for sales teams to explore additional therapeutic areas. This diversification can lead to cross-selling opportunities and increased market penetration within the biotechnology industry.
Financial Health With a revenue range of $0 - 10M and recent funding of $10M, SwanBio Therapeutics demonstrates financial stability and investment interest. Sales professionals can leverage this financial backing to negotiate advantageous deals and secure long-term partnerships with confidence in the company's financial health.
Competitive Landscape Awareness Knowing similar companies like NorthSea Therapeutics and Escient Pharmaceuticals, with varying employee sizes and revenue ranges, provides insights for competitive positioning strategies. Sales development representatives can tailor their approach to highlight SwanBio's unique offerings and competitive advantages in the market.
Industry Collaboration SwanBio's location in Bala Cynwyd, Pennsylvania, a hub for biotechnology research, presents opportunities for industry collaborations and networking. Sales professionals can leverage the company's strategic location to build relationships with local partners, enhancing market presence and driving sales growth in the region.
| SwanBio Therapeutics Email Formats | Percentage |
| FLast@swanbiotx.com | 98% |
| Last@swanbiotx.com | 1% |
| FMLast@swanbiotx.com | 1% |
Biotechnology ResearchPennsylvania, United States11-50 Employees
SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.
Company Overview
Funding & FinancialsSwanBio Therapeutics has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Oct 04, 2023 in the amount of $10M.
SwanBio Therapeutics's revenue is in the range of $10M
Funding & FinancialsSwanBio Therapeutics has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Oct 04, 2023 in the amount of $10M.
SwanBio Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com